Human Phospholipases

Abstract

The invention provides human lipid metabolism enzymes (LME) and polynucleotides which identify and encode LME. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of LME.

1 .- 28 . (canceled) 
     
     
         29 . A substantially purified polypeptide comprising an amino acid sequence of SEQ ID NO:5. 
     
     
         30 . The polypeptide of  claim 29 , further comprising a signal sequence. 
     
     
         31 . The polypeptide of  claim 29 , further comprising a label. 
     
     
         32 . The polypeptide of  claim 29 , linked to a heterologous polypeptide. 
     
     
         33 . A composition comprising the polypeptide of  claim 29  and a pharmaceutically acceptable excipient. 
     
     
         34 . A substantially purified polypeptide variant of SEQ ID NO:5, wherein the variant differs from SEQ ID NO:5 at one or more amino acids selected from the group consisting of: T72, S14, S16, S97, S144, T175, S206, S258, S272, S287, T320, T47, T68, S121, T124, T348, N50, N58, N66, and N357. 
     
     
         35 . A substantially purified polypeptide fragment of SEQ ID NO:5, wherein the fragment is selected from the group consisting of: amino acids P188-H205, L211-P231, N64-1335, L39-V333, M1-A18, H31-D319, N 102 -1116, D146-S160, Y223-C233, S59-F78, V104-H119, D147-E165, C246-E261, P325-K340, and a combination thereof. 
     
     
         36 . A substantially purified polypeptide variant having at least 95% identity to SEQ ID NO:5, wherein the variant differs from SEQ ID NO:5 at one or more amino acids selected from the group consisting or: T348, N357, P188-H205, L211-P231, N64-1335, L39-V333, M1-A18, H31-D319, N 102 -1116, D146-S160, Y223-C233, S59-F78, V104-H119, D147-E165, C246-E261, and P325-K340. 
     
     
         37 . A substantially purified polypeptide consisting of an amino acid sequence of SEQ ID NO:5. 
     
     
         38 . An isolated polypeptide comprising an amino acid sequence having at least about 95% sequence identity to an amino acid sequence of SEQ ID NO:5, wherein the polypeptide has phospholipase activity. 
     
     
         39 . The isolated polypeptide of  claim 38  comprising a fragment of the amino acid sequence of SEQ ID NO:5. 
     
     
         40 . A composition comprising the polypeptide of  claim 38  and a pharmaceutically acceptable excipient. 
     
     
         41 . A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:5 and fragments thereof, the method comprising the steps of:
 a) culturing a host cell containing an expression vector containing at least a fragment of a polynucleotide encoding the amino acid sequence of SEQ ID NO:5 under conditions suitable for the expression of the polypeptide; and   b) recovering the polypeptide from the host cell culture.   
     
     
         42 . A purified antibody which specifically binds to the polypeptide of  claim 29 . 
     
     
         43 . A purified antibody which specifically binds to the polypeptide fragment of  claim 35 .